Serina Therapeutics, a clinical-stage biotech specializing in polymer drug delivery via its proprietary POZ platform, continues progressing its lead candidate SER-252 through Phase 1b trials targeting advanced Parkinson’s disease. Despite promising technology advantages over PEG polymers and strategic collaborations including a Pfizer license, the company reported widening operating losses in 2025 and limited cash reserves, reflecting ongoing investment in R&D without revenue generation. Key near-term catalysts include clinical readouts for SER-252 and potential deal developments, while substantial regulatory, financial, and developmental risks persist along the path to commercialization.